Cyclin-dependent kinase modulators and cancer therapy (Q38038670)

27 August 2017

Cyclin-dependent kinase modulators and cancer therapy (English)

1 reference

27 August 2017

Marialucia Gallorini

1

1 reference

PubMed ID

22928661

27 August 2017

Amelia Cataldi

series ordinal

2

1 reference

PubMed ID

22928661

27 August 2017

Viviana di Giacomo

series ordinal

3

1 reference

27 August 2017

1 December 2012

1 reference

27 August 2017

1 reference

27 August 2017

26

1 reference

27 August 2017

6

1 reference

27 August 2017

377-391

1 reference

G1 events and regulation of cell proliferation

27 August 2017

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cell cycle control in normal and neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

To cycle or not to cycle: a critical decision in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Regulation of cyclin-Cdk activity in mammalian cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cyclins and their associated cyclin-dependent kinases in the human cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

The Rb/E2F pathway: expanding roles and emerging paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A cyclin-dependent kinase-activating kinase (CAK) in budding yeast unrelated to vertebrate CAK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A novel cyclin associates with MO15/CDK7 to form the CDK-activating kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

The Cdk-activating kinase (CAK) from budding yeast.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Crystal structure of cyclin-dependent kinase 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Structural basis for inhibition of the cyclin-dependent kinase Cdk6 by the tumour suppressor p16INK4a

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Secrets of a double agent: CDK7 in cell-cycle control and transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Association of Cdk-activating kinase subunits with transcription factor TFIIH

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cdk-activating kinase complex is a component of human transcription factor TFIIH

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

CTD kinase associated with yeast RNA polymerase II initiation factor b.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A carboxyl-terminal-domain kinase associated with RNA polymerase II transcription factor delta from rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Dual phosphorylation of the T-loop in cdk7: its role in controlling cyclin H binding and CAK activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cdk7 is essential for mitosis and for in vivo Cdk-activating kinase activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

The crystal structure of human CDK7 and its protein recognition properties

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

cdk-7 Is required for mRNA transcription and cell cycle progression in Caenorhabditis elegans embryos

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Control of cell division and transcription by cyclin-dependent kinase-activating kinases in plants.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Substrate specificity of the cdk-activating kinase (CAK) is altered upon association with TFIIH

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Regulation of CDK7 substrate specificity by MAT1 and TFIIH.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

T-loop phosphorylation stabilizes the CDK7-cyclin H-MAT1 complex in vivo and regulates its CTD kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

PITALRE, a nuclear CDC2-related protein kinase that phosphorylates the retinoblastoma protein in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

The role of the Cdk9/Cyclin T1 complex in T cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Role of the cyclin-dependent kinase 9-related pathway in mammalian gene expression and human diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

P-TEFb, a cyclin-dependent kinase controlling elongation by RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Identification of a novel isoform of Cdk9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cdk9/Cyclin T1 complex: a key player during the activation/differentiation process of normal lymphoid B cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

CD27 is acquired by primed B cells at the centroblast stage and promotes germinal center formation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

MyoD recruits the cdk9/cyclin T2 complex on myogenic-genes regulatory regions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Peroxisome proliferator-activated receptor gamma recruits the positive transcription elongation factor b complex to activate transcription and promote adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Antiapoptotic function of Cdk9 (TAK/P-TEFb) in U937 promonocytic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cdk9 regulates neural differentiation and its expression correlates with the differentiation grade of neuroblastoma and PNET tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Protein kinase inhibitors: insights into drug design from structure.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

CDK inhibitors: positive and negative regulators of G1-phase progression

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cyclin-dependent kinase pathways as targets for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Specific protection against breast cancers by cyclin D1 ablation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A novel cyclin encoded by a bcl1-linked candidate oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Molecular pathogenesis and a consequent classification of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

21 January 2018

E2F-1 induced apoptosis

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Residues phosphorylated by TFIIH are required for E2F-1 degradation during S-phase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Direct repression of the Mcl-1 promoter by E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

E2F-1 potentiates cell death by blocking antiapoptotic signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A p34(cdc2) survival checkpoint in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Preclinical and clinical development of cyclin-dependent kinase modulators

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Development of cyclin-dependent kinase modulators as novel therapeutic approaches for hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A phase II evaluation of flavopiridol as second-line chemotherapy of endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A phase I clinical trial of the sequential combination of irinotecan followed by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Chemoprevention of mouse intestinal tumorigenesis by the cyclin-dependent kinase inhibitor SNS-032

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Roscovitine targets, protein kinases and pyridoxal kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A small molecule-kinase interaction map for clinical kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

The cyclin-dependent kinase inhibitor seliciclib (R-roscovitine; CYC202) decreases the expression of mitotic control genes and prevents entry into mitosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Selective cyclin-dependent kinase inhibitors discriminating between cell cycle and transcriptional kinases: future reality or utopia?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Roscovitine inhibits differentiation and invasion in a three-dimensional skin reconstruction model of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

R-roscovitine (Seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Chromosome translocations: dangerous liaisons revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Genomics and cancer drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

Human general transcription factor IIH phosphorylates the C-terminal domain of RNA polymerase II

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11634060-000000000-00000

10.2165/11634060-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22928661